Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Rak prostaty, ryzyko genetyczne i sprawiedliwe badania przesiewowe (ProGRESS) (ProGRESS)

10 listopada 2026 zaktualizowane przez: VA Office of Research and Development

Rak prostaty, ryzyko genetyczne i sprawiedliwe badania przesiewowe (ProGRESS): pragmatyczna próba precyzyjnych badań przesiewowych w kierunku raka prostaty

Prostate cancer is the most common non-skin cancer among Veterans and the second leading cause of male cancer death. Current methods of screening men for prostate cancer are inaccurate and cannot identify which men do not have prostate cancer or have low-grade cases that will not cause harm and which men have significant prostate cancer needing treatment. False-positive screening tests can result in unnecessary prostate biopsies for men who do not need them. However, new genetic testing might help identify which men are at highest risk for prostate cancer. This study will examine whether a genetic test helps identify men at risk for significant prostate cancer while helping men who are at low risk for prostate cancer avoid unnecessary biopsies. If this genetic test proves beneficial, it will improve the way that healthcare providers screen male Veterans for prostate cancer.

Przegląd badań

Status

Rekrutacyjny

Warunki

Szczegółowy opis

Prostate cancer is the most common non-cutaneous cancer in US men and in the Veterans Health Administration (VHA): 1 in 8 will be diagnosed with the disease in their lifetime. Many cases are non-lethal, but prostate cancer remains the 2nd leading cause of cancer death among US men, representing 2.5% of all deaths. VHA diagnoses >16,000 new cases annually and cares for >400,000 men living with prostate cancer. As a result, prostate cancer diagnosis and treatment is a national priority for VHA.

A major impediment to reducing the incidence of metastatic prostate cancer and prostate cancer death is the lack of an optimal screening strategy to identify men at high risk. Screening with prostate-specific antigen (PSA) testing modestly reduces prostate cancer deaths but at the cost of overdiagnoses and overtreatment. Current screening approaches do not adequately distinguish men without prostate cancer or with low-grade prostate cancer amenable to active surveillance from men with clinically significant prostate cancer, who need treatment. As a result, clinical guidelines do not recommend universal prostate cancer screening, including those from the United States Preventive Services Task Force (USPSTF) and the VHA National Center for Health Promotion and Disease Prevention. Still, many men undergo screening based on variable and subjective assessments of their race/ethnicity, family history, and other risk factors.

A new paradigm of precision screening could improve the benefit-to-harm ratio of screening by implementing screening strategies tailored to an individual's specific genetic profile. Due to advances in high-throughput genotyping and sequencing, increasingly large and diverse cohort studies, and standardization of genetic variant classification, germline genetic testing is emerging as a powerful predictor for prostate cancer, including metastatic and lethal disease. This includes both rare highly penetrant variants and polygenic risk scores (PRS), which characterize an individual's predisposition to prostate cancer due to common genetic variation. Rare and common genetic variation is now an equally powerful predictor of clinically significant disease as self-reported race or family history, including in the Million Veteran Program.

This clinical trial will evaluate the promise of precision risk stratification to identify men most likely to benefit from prostate cancer screening. During the proof-of-concept phase, the investigators will achieve the following aims:

  1. Develop a precision prostate cancer screening intervention consisting of genetic testing for rare variants and a transancestry PRS, delivered to participants and their primary care providers along with individualized, genetic risk-informed screening recommendations.
  2. Determine the feasibility of enrolling men aged 55-70 ( 35% of whom are of racial/ethnic minority groups) to a pragmatic randomized clinical trial (RCT) comparing the precision screening intervention to usual care.
  3. Perform an interim assessment to determine whether the observed trajectory of negative prostate biopsy event rates is consistent with rates needed to detect a meaningful between-group difference at the end of the 7-year project period.

Following demonstration of enrollment feasibility and observation of adequate event rates during the proof-of-concept phase, the RCT will continue to the clinical trial phase to test the following co-primary hypotheses:

  1. Compared with men in the usual care arm, men in the precision screening arm will have a higher incidence rate of clinically significant prostate cancer (csPCa, defined as NCCN classification intermediate risk or higher) detection over the trial follow-up period.
  2. Compared with men in the usual care arm, men in the precision screening arm will have a lower incidence rate of negative prostate biopsies over the trial follow-up period.

Pre-specified subgroup analyses will test these hypotheses in Black men specifically, to evaluate whether this population benefits equally or more from the intervention. Enrollees will be followed for additional outcomes including all prostate cancer diagnoses, PSA testing, prostate MRI, rare variants identified, preferences for or against prostate cancer screening, and health-related quality of life.

The investigators expect that precision screening will increase screening among high-risk patients but decrease screening among low- and average-risk patients, thereby maintaining or improving overall csPCa detection while improving the population-level benefit-to-harm ratio. Rigorous RCT evidence that genetic risk-informed screening maintains the benefits of screening while minimizing the harms of unnecessary procedures and treatments among low-risk men will change clinical practice and policy around prostate cancer screening.

Typ studiów

Interwencyjne

Zapisy (Szacowany)

5000

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Lokalizacje studiów

    • Massachusetts
      • Boston, Massachusetts, Stany Zjednoczone, 02130-4817
        • Rekrutacyjny
        • VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
        • Kontakt:
        • Główny śledczy:
          • Jason L Vassy, MD MPH

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

55 lat do 69 lat (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Tak

Płeć kwalifikująca się do nauki

Męski

Opis

Inclusion Criteria:

  • baseline age 55-69 years
  • receipt of regular VA care
  • Veteran status

Exclusion Criteria:

  • personal history of prostate cancer
  • prior prostate biopsy, prostatectomy, or prostate MRI
  • known carrier status of rare variant associated with cancer syndrome

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Ekranizacja
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Pojedynczy

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Precision screening intervention

The precision screening intervention will consist of an interpreted prostate cancer genetic risk assessment (GRA) report, provided to the participant along with tailored prostate cancer screening recommendations and, in cases of high genetic risk, genetic counseling. The risk report and supporting educational materials will also be provided to the participant's primary care provider. Usual care in this study includes receipt of a brief brochure about shared decision-making in prostate cancer screening.

The precision screening intervention will consist of an interpreted prostate cancer genetic risk assessment (GRA) report, provided to the participant along with tailored prostate cancer screening recommendations and, in cases of high genetic risk, genetic counseling. The risk report and supporting educational materials will also be provided to the participant's primary care provider. Usual care in this study includes receipt of a brief brochure about shared decision-making in prostate cancer screening.

Usual care in this study includes receipt of a brief brochure about shared decision-making in prostate cancer screening.

Eksperymentalny: Usual care

Usual care in this study includes receipt of a brief brochure about shared decision-making in prostate cancer screening.

Usual care in this study includes receipt of a brief brochure about shared decision-making in prostate cancer screening.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Diagnosis of clinically significant prostate cancer
Ramy czasowe: 7 years

Cases of csPCa will be abstracted from VA and survey data and defined using NCCN classifications of intermediate risk or higher: PSA 10 and/or Grade Group 2 and/or clinical T stage T2b

7 years
Negative prostate biopsy
Ramy czasowe: 7 years

Counts of negative prostate biopsies not temporally associated with csPCa (within 6 months of diagnosis) will be abstracted from VA and survey data

7 years

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Diagnosis of prostate cancer
Ramy czasowe: 7 years

All cases of prostate cancer will be abstracted from VA and survey data

7 years
Prostate biopsy
Ramy czasowe: 7 years

Counts of all prostate biopsies will be abstracted from VA and survey data.

7 years
PSA testing
Ramy czasowe: 7 years

PSA testing will be identified from VA and survey data

7 years
Prostate MRI
Ramy czasowe: 7 years

Prostate magnetic resonance imaging will be identified from VA and survey data

7 years
Self-rated health
Ramy czasowe: 7 years

Self-rated health will be collected at the baseline survey and every 6 months with a single-item self-rating of health on a Likert scale from "poor" to "excellent.

7 years
Quality of life
Ramy czasowe: 5 years

Health-related quality of life is collected through the Veterans RAND 12-Item Health Survey (VR-12) on the baseline survey and at each participant's 5-year survey or last survey

5 years

Inne miary wyników

Miara wyniku
Opis środka
Ramy czasowe
Adherence to precision cancer screening recommendations
Ramy czasowe: 7 years

The precision screening intervention will include the recommendation that high-risk men undergo PSA screening and that low-risk men not undergo screening. The investigators will define adherence to the intervention in these two groups of men as the presence and absence of PSA testing, respectively, during the observation period.

7 years
Acceptability of the precision prostate cancer screening intervention
Ramy czasowe: 7 years

The survey will assess patient acceptability of the precision screening with a 3-item instrument assessing patient perspective on the 1) amount of information presented, 2) length of the information, 3) clarity of the information, with each domain scored on a 5-point Likert scale.

7 years
Rare pathogenic/likely pathogenic variants
Ramy czasowe: 7 years

Proportion of participants with a rare P/LP variant associated with hereditary prostate cancer

7 years

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Śledczy

  • Główny śledczy: Jason L Vassy, MD MPH, VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

1 lutego 2024

Zakończenie podstawowe (Szacowany)

30 września 2029

Ukończenie studiów (Szacowany)

30 września 2030

Daty rejestracji na studia

Pierwszy przesłany

21 czerwca 2023

Pierwszy przesłany, który spełnia kryteria kontroli jakości

21 czerwca 2023

Pierwszy wysłany (Rzeczywisty)

3 lipca 2023

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

13 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

10 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Opis planu IPD

Individual participant data will be stored in a data repository available for request by approved individuals.

Kryteria dostępu do udostępniania IPD

Requestors may be required to have IRB approval, data use agreements, and other regulatory and administrative credentials and authorizations prior to receiving data.

Typ informacji pomocniczych dotyczących udostępniania IPD

  • PROTOKÓŁ BADANIA
  • SOK ROŚLINNY
  • ANALITYCZNY_KOD

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

produkt wyprodukowany i wyeksportowany z USA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj